Abstract
A nanoscale drug carrier could have a variety of therapeutic and diagnostic uses provided that the carrier is biocompatible in vivo. Carbon nano-onions (CNOs), are one such potential carbon-based drug carrier. Previous work in our laboratory showed that single and repeated intravenous administration of CNOs (125, 250 or 500 μg) was well-tolerated by BALB/c mice (n=5 mice per group). Hence, this study aimed to investigate the extent of CNO accumulation in various organs as well as its effect on drug metabolism and oxidative stress.